Epidemiology of non-alcoholic fatty liver disease

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 155-161

  Bellentani, Stefano ^a,c   Scaglioni, Federica ^a   Marino, Mariano ^a   Bedogni, Giorgio ^a,b  

^a AUSL Modena   (Italy)

^b Centro Studi Fegato   (Italy)

^c Ospedale 'Ramazzini'   (Italy)

Author keywords

Epidemiology; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

AMINOTRANSFERASE; LIVER ENZYME;

AGE; AMINOTRANSFERASE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; ECHOGRAPHY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; SEX RATIO;

ADULT; AGED; FATTY LIVER; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 77952576769     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282080     Document Type: Review

References (77)

1. Angulo P, Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17(Suppl):S186-S190.
2. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
3. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
4. Lonardo A, Loria P: NAFLD and cardiovasular risk: direct evidence for the tale of two ages. Am J Gastroenterol 2009;104:1851-1852.
5. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
6. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
7. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P: Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22(suppl 2):64-70.
8. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
9. Bellentani S, Marino M: Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8(suppl 1):S4-S8.
10. Graham A: Curcumin adds spice to the debate: lipid metabolism in liver disease. Br J Pharmacol 2009;157:1352-1353.
11. Alkhouri N, Dixon LJ, Feldstein AE: Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009;3:445-451.
12. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A: Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009;50:772-780.
13. Bedogni G, Bellentani S: Fatty liver: How frequent is it and why? Ann Hepatology 2004;3:63-65.
14. Loria P, Lonardo A, Carulli N: Should nonalcoholic fatty liver disease be renamed? Dig Dis 2005;23:72-82.
15. Dorland NW: Dorland's Illustrated Medical Dictionary, ed. 28. Philadelphia, WB Saunders Company, 1994.
16. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ: Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-1766.
17. Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, Nakajima T, Miwa S, Murai Y, Hayashi S, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y: Nonalcoholic steato-hepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008;38:1241-1251.
18. Clark JM, Diehl AM: Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-3004.
19. Björnsson E, Angulo P: Non-alcoholic fatty liver disease. Scand J Gastroenterol 2007;42:1023-1030.
20. Hilden M, Christof fersen P, Juhl E, Dalgaard JB: Liver histology in a 'normal' population: examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597.
21. Ground KE: Liver pathology in aircrew. Aviat Space Environ Med 1982;53:14-18.
22. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110.
23. McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-533.
24. Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP, Prieto J: Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000;47:429-435.
25. Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Fulcher AS, Posner MP: Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000;69:1375-1379. (Pubitemid 30238727)
26. Hwang S, Lee SG, Jang SJ, Cho SH, Kim KH, Ahn CS, Moon DB, Ha TY: The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 2004;10:721-725.
27. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
28. Marceau P: Contribution of bariatric surgery to the comprehension of morbid obesity. Obes Surg 2005;15:3-10.
29. Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D: Liver damage in obese patients. Obes Surg 2002;12:802-804.
30. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-226.
31. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF: Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355.
32. Kral JG: Patient selection for treatment of obesity. Surg Obes Relat Dis 2005;1:126-132.
33. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
34. Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004;16:1087-1093.
35. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005;42:44-52.
36. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:521-528.
37. Lonardo A, Bellini M, Tartoni P, Tondelli E: The bright liver syndrome. Prevalence and determinants of a 'bright' liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351-356.
38. Omagari K, Kadokawa Y, Masuda J, et al: Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17:1098-1105.
39. Araujo LM, De Oliveira DA, Nunes DS: Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 1998;24:458-462.
40. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L: Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastroin-testin Liver Dis 2008;17:255-260.
41. El-Hassan AY, Ibrahim EM, al-Mulhim FA, Nabhan AA, Chammas MY: Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992;65:774-778.
42. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
43. Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ: Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 2003;48:797-801.
44. Ong JP, Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16, vii.
45. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R: Clinicopathologic study of alcohol-like liver disease in non-alcoholics;non- alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521-528.
46. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y: Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hyper tens 1995;9:101-105.
47. Kawai N, Tsugaya M, Sakagami H, Sasaki S, Kohri K: A study of the indication for conservative surgery in adult hydronephrosis based on presurgery post-contrast computed tomography (CT) finding (in Japanese). Nippon Hinyokika Gakkai Zasshi 1997;88:997-1004.
48. Tazawa Y, Noguchi H, Nishinomiya F, Takada G: Effect of weight changes on serum transaminase activities in obese children. Acta Paediatr Jpn 1997;39:210-214.
49. Rashid M, Roberts EA: Nonalcoholic steato-hepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
50. Browning JD: Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006;44:466-471.
51. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
52. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
53. Frith J, Day CP, Henderson E, Burt AD, Newton JL: Non-alcoholic fatty liver disease in older people. Gerontology 2009;55:607-613.
54. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
55. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
56. Diehl AM, Goodman Z, Ishak KG: Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
57. Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-598.
58. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.
59. Clark JM, Diehl AM: Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-250.
60. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N, POLI. ST.E.N.A. Study Group: Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of nonalcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34:204-211.
61. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-2455.
62. Skelly MM, James PD, Ryder SD: Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-199.
63. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT va lues. Hepatology 2003;37:1286-1292.
64. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M: Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014.
65. Hilden M, Christof fersen P, Juhl E, Dalgaard JB: Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597.
66. Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH: Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21:109-113.
67. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
68. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
69. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N: Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801. (Pubitemid 32851301)
70. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
71. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B, RISC Investigators: Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49:1537-1544.
72. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062. (Pubitemid 41338752)
73. Ong JP, Pitts A, Younossi ZM: Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-612.
74. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, et al: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007;191:391-396.
75. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS: Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935-1944.
76. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G: The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study. Diabet Med 2006;23:1270-1271.
77. Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S: Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387-1391.